Advertisement

Topics

Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%

22:26 EDT 9 Jul 2019 | Proactive Investors

Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia.

Original Article: Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%

NEXT ARTICLE

More From BioPortfolio on "Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%"

Advertisement
Quick Search
Advertisement
Advertisement